60 related articles for article (PubMed ID: 14584968)
1. Nedaplatin: a cisplatin derivative in cancer chemotherapy.
Shimada M; Itamochi H; Kigawa J
Cancer Manag Res; 2013; 5():67-76. PubMed ID: 23696716
[TBL] [Abstract][Full Text] [Related]
2. Monofunctional and higher-valent platinum anticancer agents.
Johnstone TC; Wilson JJ; Lippard SJ
Inorg Chem; 2013 Nov; 52(21):12234-49. PubMed ID: 23738524
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of 1,2-diaminocyclohexane--platinum complexes against sarcoma-180 ascites form.
Kidani Y; Inagaki K; Iigo M; Hoshi A; Kuretani K
J Med Chem; 1978 Dec; 21(12):1315-8. PubMed ID: 722741
[TBL] [Abstract][Full Text] [Related]
4. Platinum anticancer drugs. From serendipity to rational design.
Monneret C
Ann Pharm Fr; 2011 Nov; 69(6):286-95. PubMed ID: 22115131
[TBL] [Abstract][Full Text] [Related]
5. Status of bi- and multi-nuclear platinum anticancer drug development.
Zhang J; Wang L; Xing Z; Liu D; Sun J; Li X; Zhang Y
Anticancer Agents Med Chem; 2010 May; 10(4):272-82. PubMed ID: 20184553
[TBL] [Abstract][Full Text] [Related]
6. The current status of new platinum analogs.
Christian MC
Semin Oncol; 1992 Dec; 19(6):720-33. PubMed ID: 1462169
[TBL] [Abstract][Full Text] [Related]
7. Lobaplatin induces apoptosis in T24 and 5637 bladder cancer cells by regulating Bcl-2 and Bax expression and inhibiting the PI3K/Akt signaling pathway.
Yu Q; Lan T; Ma Z; Wang Z; Zhang C; Jiang Y; Zhao Z
Transl Androl Urol; 2023 Aug; 12(8):1296-1307. PubMed ID: 37680227
[TBL] [Abstract][Full Text] [Related]
8. Clinical developments of antitumor polymer therapeutics.
Parveen S; Arjmand F; Tabassum S
RSC Adv; 2019 Aug; 9(43):24699-24721. PubMed ID: 35528643
[TBL] [Abstract][Full Text] [Related]
9. Retrospective study of the efficacy and toxicity of lobaplatin in combined chemotherapy for metastatic breast cancer.
Wu Y; Xu XY; Yan F; Sun WL; Zhang Y; Liu DL; Shen B
Onco Targets Ther; 2019; 12():4849-4857. PubMed ID: 31417282
[TBL] [Abstract][Full Text] [Related]
10. Lobaplatin Inhibits Prostate Cancer Proliferation and Migration Through Regulation of BCL2 and BAX.
Cao H; Feng Y; Chen L; Yu C
Dose Response; 2019; 17(2):1559325819850981. PubMed ID: 31217754
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and individualized lobaplatin regimen for the treatment of Chinese small cell lung cancer in the elderly.
Cheng Y; Wu L; Liu X; Zhao Y; Liu C; Chen Q; Sun T; Zheng Q
Medicine (Baltimore); 2019 Jan; 98(3):e14136. PubMed ID: 30653145
[TBL] [Abstract][Full Text] [Related]
12. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.
Johnstone TC; Suntharalingam K; Lippard SJ
Chem Rev; 2016 Mar; 116(5):3436-86. PubMed ID: 26865551
[TBL] [Abstract][Full Text] [Related]
13. Advances in drug delivery system for platinum agents based combination therapy.
Kang X; Xiao HH; Song HQ; Jing XB; Yan LS; Qi RG
Cancer Biol Med; 2015 Dec; 12(4):362-74. PubMed ID: 26779373
[TBL] [Abstract][Full Text] [Related]
14. Lobaplatin inhibits growth of gastric cancer cells by inducing apoptosis.
Yin CY; Lin XL; Tian L; Ye M; Yang XY; Xiao XY
World J Gastroenterol; 2014 Dec; 20(46):17426-33. PubMed ID: 25516654
[TBL] [Abstract][Full Text] [Related]
15. Lobaplatin: D 19466.
Drugs R D; 2003; 4(6):369-72. PubMed ID: 14584968
[TBL] [Abstract][Full Text] [Related]
16. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.
Gietema JA; Veldhuis GJ; Guchelaar HJ; Willemse PH; Uges DR; Cats A; Boonstra H; van der Graaf WT; Sleijfer DT; de Vries EG
Br J Cancer; 1995 Jun; 71(6):1302-7. PubMed ID: 7779728
[TBL] [Abstract][Full Text] [Related]
17. Lobaplatin: a new antitumour platinum drug.
McKeage MJ
Expert Opin Investig Drugs; 2001 Jan; 10(1):119-28. PubMed ID: 11116285
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
19. A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer.
Kavanagh JJ; Edwards CL; Freedman RS; Finnegan MB; Balat O; Tresukosol D; Burk K; Loechner S; Hord M; Franklin JL
Gynecol Oncol; 1995 Jul; 58(1):106-9. PubMed ID: 7789874
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
